Navigation Links
Potential Treatment for Huntington's Disease, Found Effective, Safe in Mice, Monkeys, Enters Clinical Testing
Date:2/26/2016

MINNEAPOLIS, Feb. 26, 2016 /PRNewswire-USNewswire/ -- A drug that would be the first to target the cause of Huntington's disease (HD) is effective and safe when tested in mice and monkeys, according to data released today that will be presented at the American Academy of Neurology's 68th Annual Meeting in Vancouver, Canada, April 15 to 21, 2016. A study to test the drug in humans has begun.

Huntington's disease is a rare, hereditary disease that causes uncontrolled movements, loss of intellectual abilities, emotional problems and eventually death. The disease is passed from parent to child through a mutation in the huntingtin gene. The mutation results in the production of a disease-causing huntingtin protein. Each child has a 50/50 chance of inheriting the gene mutation. Everyone who inherits the mutated gene will eventually develop the disease.

The new drug, called IONIS-HTTRx, is an antisense drug that acts as a "gene silencer" to inhibit the production of huntingtin protein in people with Huntington's disease.

"It is very exciting to have the possibility of a treatment that could alter the course of this devastating disease," said clinical study principal investigator Blair R. Leavitt, MD, of the University of British Columbia in Vancouver. "Right now we only have treatments that work on the symptoms of the disease." Leavitt notes the drug is still years away from being used in human clinical practice.

Earlier studies in mouse models of Huntington's disease showed that treatment with antisense drugs delays disease progression and results in sustained reversal of the disease phenotype. In YAC128 mice, a transgenic model of HD, motor deficits improved within one month of initiating antisense treatment and were restored to normal at two months after treatment termination. Motor skills of antisense-treated BACHD mice, another transgenic model of HD, improved eight weeks after initiation of treatment and persisted for at least nine months after treatment termination. In monkeys, dose-dependent reductions in HTT mRNA and Htt protein throughout the central nervous system were observed after intrathecal administration of an antisense drug. Reduction of cortical huntingtin levels by 50 percent was readily achieved in monkeys and correlated with 15 to 20 percent reduction in the caudate. In further tests in rodents and monkeys, IONIS-HTTRx was found to be well-tolerated without any dose-limiting side effects. 

The drug is now in a Phase 1/2a clinical study. The drug is delivered into the cerebral spinal fluid via an intrathecal injection in the lumbar space, as antisense drugs do not cross the blood brain barrier. In the current clinical study, the drug is administered in four doses at monthly intervals. Different doses of the drug will be evaluated for safety and tolerability. In addition, drug pharmacokinetics will be characterized and effects of the drug on specific biomarkers and clinical outcomes will be examined. 

The drug was developed by scientists at Ionis Pharmaceuticals in collaboration with their partners CHDI Foundation, Roche Pharmaceuticals and academic collaborators at University of California, San Diego. The preclinical studies were conducted by Ionis Pharmaceuticals. The ongoing clinical study is supported by Ionis Pharmaceuticals and is part of Ionis' collaboration with Roche to develop antisense drugs to treat Huntington's disease.

Learn more about Huntington's disease at www.aan.com/patients.

The American Academy of Neurology, an association of 30,000 neurologists and neuroscience professionals, is dedicated to promoting the highest quality patient-centered neurologic care. A neurologist is a doctor with specialized training in diagnosing, treating and managing disorders of the brain and nervous system such as Alzheimer's disease, stroke, migraine, multiple sclerosis, brain injury, Parkinson's disease and epilepsy.

For more information about the American Academy of Neurology, visit http://www.aan.com or find us on Facebook, Twitter, Google+ and YouTube.

 


'/>"/>
SOURCE American Academy of Neurology
Copyright©2016 PR Newswire.
All rights reserved


Related medicine technology :

1. New Emergence of Potential Tx & Dx Options Predicted to Transform the Current Landscape for Liver Diseases (NASH) to a $35 Billion Opportunity
2. Ameritox Research Confirms Significant Spike in Potential Nonadherence to Opioid Medications
3. Ameritox Data on ADHD Stimulant Prescriptions Uncovers Significant Rates of Illicit Drug Use and Potential Nonadherence to Drug Regimen
4. Eisais Lenvatinib Receives FDA Priority Review for the Potential Treatment of Advanced Renal Cell Carcinoma in Combination with Everolimus
5. Largest Breast Cancer Study of its Kind Suggests Several New Potential Drug Targets and Combinations
6. U.S. and European Regulators Accept Applications for AbbVies Venetoclax, the First Potential BCL-2 Inhibitor for Chronic Lymphocytic Leukemia
7. Rebiotix and Washington University Treat First Patient with Urinary Tract Infection Utilizing Investigational RBX2660 to Potentially Reverse Multidrug Resistant Organisms
8. Phoenix PharmaLabs Releases New Data Confirming That Their Novel Opioid Shows No Signs of Addiction Potential
9. U-M startup company secures license, funding to test potential drugs aimed at endocrine disorders
10. Merrimack Amends MM-121 Phase 2 Clinical Study in Heregulin-Positive Non-Small Cell Lung Cancer to Support Potential Registration
11. Caris Life Sciences Non-Invasive Liquid Biopsy Platform ADAPT Biotargeting System Demonstrates Potential to Improve Accuracy of Breast Cancer Diagnosis
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/14/2017)... HACKENSACK, N.J. and PETACH TIKVAH, ... Therapeutics Inc. (NASDAQ: BCLI), a leading developer of adult ... for the second quarter ending June 30, 2017. ... advanced stages of preparing for our pivotal Phase 3 ... Chaim Lebovits , President and Chief Executive Officer ...
(Date:8/7/2017)... Md. , Aug. 7, 2017 ... healthcare member acquisition, retention, and engagement, announced the ... of Strategy and Product Development, effective as of ... consulting and technology implementation strategy for our clients. ... of experience in consulting and business analytics within ...
(Date:8/4/2017)... -- The search for test results that can be ... long been the goal of healthcare providers and the ... largest meeting of lab professionals and IVD firms this ... Kalorama Information.  The firm said scores of companies with ... and software were at the American Association for Clinical ...
Breaking Medicine Technology:
(Date:8/16/2017)... Angeles, California (PRWEB) , ... August 16, 2017 , ... An August 3rd article ... that was the subject of a report in JAMA (the Journal of the American Medical ... above 50 were able to achieve BMIs under 30, when compared to patients with lower ...
(Date:8/16/2017)... FL (PRWEB) , ... August 16, 2017 , ... ... standardized product data and images announced today that it was acquired by Advantage ... Industry’s solution for product information. IX-ONE’s members include the industry’s leading suppliers, brokers, ...
(Date:8/16/2017)... ... August 16, 2017 , ... In 1987, ... celebrate 30 years in business this year, and they’re marking the milestone by ... to serve their patients. , It stands to reason that, given the ...
(Date:8/16/2017)... ... August 16, 2017 , ... Modern Consulting Insurance & ... program. Partnering once again with Boys & Girls Clubs of Greater Kansas City, ... area’s very own American Idol. With all proceeds benefitting local worthy causes, donations ...
(Date:8/16/2017)... ... August 16, 2017 , ... Paul Vitenas, MD, FACS ... 2017 Top Doctor. The annual list identifies the nation’s top physicians, in a variety ... made it to the top of Castle Connolly’s coveted ranking. , Castle Connolly is ...
Breaking Medicine News(10 mins):